Abstract Number: 0539 • ACR Convergence 2022
Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use
Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…Abstract Number: 0986 • ACR Convergence 2022
Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)
Background/Purpose: ACCESS assessed the efficacy of abatacept (ABA) as induction therapy in lupus nephritis (LN), randomizing 134 patients to ABA vs. placebo on a background…Abstract Number: 1467 • ACR Convergence 2022
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…Abstract Number: 0323 • ACR Convergence 2022
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ…Abstract Number: 0540 • ACR Convergence 2022
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor…Abstract Number: 0992 • ACR Convergence 2022
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Background/Purpose: Zetomipzomib is a first-in-class selective inhibitor of the immunoproteasome that is active in multiple autoimmune disease models, including murine models of SLE and LN.…Abstract Number: 1478 • ACR Convergence 2022
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
Background/Purpose: T cells play a critical role in the pathogenicity of SLE and lupus nephritis (LN). Hence, identifying T cell co-stimulatory pathways and mediators that…Abstract Number: 2072 • ACR Convergence 2022
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
Background/Purpose: Patients with lupus nephritis (LN) are often treated with high doses of glucocorticoids and experience glucocorticoid-related toxicity. Quantifying this toxicity may be a useful…Abstract Number: 0331 • ACR Convergence 2022
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
Background/Purpose: SLE is characterized by autoantibody production. The most common lupus-specific serology is the anti-dsDNA antibody (anti-DNA). Traditionally, anti-DNA is measured by an enzyme immunoassay…Abstract Number: 0541 • ACR Convergence 2022
Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Factors
Background/Purpose: Patients with SLE have an increased risk of developing venous thrombo-embolism (VTE) based on several cohort studies, accounting for significant morbidity and mortality. Lupus…Abstract Number: 1001 • ACR Convergence 2022
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind,…Abstract Number: 1480 • ACR Convergence 2022
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Background/Purpose: Kidney disease is a common manifestation of systemic lupus erythematosus (SLE); when it presents as glomerulonephritis also known as lupus nephritis (LN), it predicts…Abstract Number: 2077 • ACR Convergence 2022
Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
Background/Purpose: Background: Early complete remission (within 12 months from diagnosis) is considered an important protective factor against development of advanced chronic kidney disease (CKD) in…Abstract Number: 0333 • ACR Convergence 2022
Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis
Background/Purpose: Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 37
- Next Page »